GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
15 mai 2024 17h00 HE
|
GT Biopharma, Inc.
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for...
FSI ANNOUNCES FIRST QUARTER, 2024 FINANCIAL RESULTS
15 mai 2024 16h30 HE
|
Flexible Solutions International, Inc
A CONFERENCE CALL IS SCHEDULED FOR THURSDAY, MAY 16, 2024, 11:00AM EASTERN TIME SEE DIAL IN NUMBER BELOW VICTORIA, BRITISH COLUMBIA, May 15, 2024 (GLOBE NEWSWIRE) -- FLEXIBLE...
Polar Power Reports First Quarter 2024 Financial Results
15 mai 2024 16h10 HE
|
Polar Power, Inc.
GARDENA, CA, May 15, 2024 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its...
Aeterna Zentaris Reports First Quarter 2024 Financial Results
14 mai 2024 18h00 HE
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Bright Mountain Media, Inc Announces First Quarter 2024 Financial Results
14 mai 2024 17h00 HE
|
Bright Mountain Media, Inc.
First quarter revenue increased by $10.9 million to $12.4 million compared to $1.5 million for the first quarter of 2023. First quarter gross margin increased by $2.6 million to $3.1 million compared...
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
14 mai 2024 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, May 14, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14 mai 2024 16h05 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
13 mai 2024 16h45 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5...
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
13 mai 2024 08h00 HE
|
Cocrystal Pharma, Inc.
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in...
NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14
10 mai 2024 14h43 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...